Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $7.66, for a total transaction of $87,684.02. Following the transaction, the director now directly owns 7,229,861 shares in the company, valued at approximately $55,380,735.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Blake Borgeson also recently made the following trade(s):
- On Tuesday, April 2nd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $8.82, for a total transaction of $100,962.54.
- On Tuesday, March 19th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $10.79, for a total transaction of $216,382.66.
- On Tuesday, March 5th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $12.06, for a total transaction of $241,851.24.
- On Tuesday, February 20th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $12.32, for a total transaction of $247,065.28.
- On Tuesday, February 6th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $9.30, for a total transaction of $106,457.10.
- On Tuesday, January 23rd, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $10.58, for a total transaction of $212,171.32.
Recursion Pharmaceuticals Price Performance
NASDAQ RXRX opened at $7.35 on Friday. Recursion Pharmaceuticals, Inc. has a 12 month low of $4.54 and a 12 month high of $16.75. The stock has a 50 day moving average of $10.73 and a 200-day moving average of $9.09.
Institutional Investors Weigh In On Recursion Pharmaceuticals
Several large investors have recently made changes to their positions in RXRX. Azzad Asset Management Inc. ADV acquired a new stake in Recursion Pharmaceuticals during the 1st quarter valued at $161,000. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in Recursion Pharmaceuticals by 12.6% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 10,362,803 shares of the company’s stock valued at $103,317,000 after purchasing an additional 1,159,023 shares during the last quarter. Oxinas Partners Wealth Management LLC acquired a new stake in Recursion Pharmaceuticals during the 1st quarter valued at $122,000. TB Alternative Assets Ltd. acquired a new stake in Recursion Pharmaceuticals during the 1st quarter valued at $706,000. Finally, Wedmont Private Capital lifted its holdings in Recursion Pharmaceuticals by 11.8% during the 1st quarter. Wedmont Private Capital now owns 18,943 shares of the company’s stock valued at $172,000 after purchasing an additional 2,000 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.
Analysts Set New Price Targets
A number of research firms have issued reports on RXRX. TD Cowen began coverage on shares of Recursion Pharmaceuticals in a research report on Friday, January 26th. They set a “market perform” rating on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $17.00 price target on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 9th. Finally, KeyCorp increased their target price on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Monday, March 4th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $12.75.
View Our Latest Analysis on RXRX
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Recommended Stories
- Five stocks we like better than Recursion Pharmaceuticals
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Comprehensive Analysis of PayPal Stock
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Intuitive Surgical Stock Can Trend Much Higher This YearÂ
- Canada Bond Market Holiday: How to Invest and Trade
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.